15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering MediciNova Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $6.00 to $10.00, a moderate spread. The average target of $8.33 sits 527% above the current $1.33. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.06 next quarter toward $-0.43 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to MediciNova Inc.
As of Jul, 3 of 3 firms rate MNOV a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MNOV EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.06 – $-0.06 · 2 analysts · +0% YoY
Next period, 2 analysts expect MediciNova Inc to earn $-0.06 a share (range $-0.06 – $-0.06), versus $-0.06 a year earlier. Full-year consensus is $-0.26, growing to $-0.43 the year after.
REVENUE · NEXT QUARTER
$75.0K
Range $0 – $150.0K · 2 analysts · -39% YoY
Revenue is expected to reach $75.0K (range $0 – $150.0K), -39.2% year-over-year. Full-year consensus is $443.5K, rising to $400.0K next year.
Top analysts covering MediciNova Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MNOV.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$5.00+275.9% to target
Overall win rate
53%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #346
Buy
$9.00+576.7% to target
Overall win rate
22%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #360
Buy
$6.00+351.1% to target
Overall win rate
30%
+ Follow
#4
LE
Lander Egaña Gorroño
HC Wainwright & Co.
Buy
$10.00+651.9% to target
Coverage
—
+ Follow
#5
Elemer Piros
Lucid Capital
Buy
$11.00+727.1% to target
Coverage
—
+ Follow
MNOV stock forecast FAQ
What is MNOV's average 12-month price target?+
The 3 analysts with a live target average $8.33 for MediciNova Inc over the next 12 months, ranging from a $10.00 high to a $6.00 low.
Is MNOV stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MNOV?+
The Street-high target is $10.00 (HC Wainwright & Co.), and the Street-low is $6.00 (Maxim Group). The average of all 3 active targets is $8.33.
How many Wall Street analysts cover MNOV?+
3 analysts have an active rating on MediciNova Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering MNOV?+
Among analysts who currently cover MNOV, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $5.00 target.
What is MediciNova Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.06 – $-0.06) across 2 analysts. Full-year EPS is projected at $-0.26, rising to $-0.43 the following year.
How much revenue is MediciNova Inc expected to report next quarter?+
Consensus revenue is $75.0K (range $0 – $150.0K). Full-year revenue is projected at $443.5K, growing to $400.0K next year.
Have analysts been upgrading or downgrading MNOV lately?+
As of Jul, 3 of 3 firms rate MNOV a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MNOV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
